Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.

Several other research firms have also commented on REGN. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a “neutral” rating in a report on Tuesday, February 6th. Royal Bank of Canada reissued an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $970.57.

Regeneron Pharmaceuticals Price Performance

REGN opened at $904.70 on Friday. The company has a 50-day moving average of $957.56 and a 200-day moving average of $889.10. The company has a market capitalization of $99.30 billion, a P/E ratio of 26.03, a PEG ratio of 2.69 and a beta of 0.11. Regeneron Pharmaceuticals has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the business posted $10.96 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post 38.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $967.50, for a total value of $346,365.00. Following the completion of the sale, the executive vice president now owns 13,431 shares in the company, valued at approximately $12,994,492.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 in the last ninety days. 8.83% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in REGN. Sunbelt Securities Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $25,000. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. O Dell Group LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $27,000. Fortitude Family Office LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. Finally, MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.